Drug · CHEMBL1908360
Comparisons in its trials207
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
1 to 20 of 207
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| EVR+rCNI vs MPA+sCNI: Incidence of Adverse Events, Serious Adverse Events and Adverse Events Leading to Study Regimen Discontinuation. | 276 of 1,014 | 152 of 1,012 | 2,026 | NCT01950819 | Trial comparisons |
| EVR+rCNI vs MPA+sCNI: Incidence of Major Cardiovascular Events. | 66 of 1,014 | 86 of 1,012 | 2,026 | NCT01950819 | Trial comparisons |
| Everolimus Plus@Reduced CNI vs MPA Plus Standard@CNI: deaths from any cause | 20 of 1,014 | 29 of 1,012 | 2,026 | NCT01950819 | Trial comparisons |
| EVR+rCNI vs MPA+sCNI: Incidence of Malignancies. | 41 of 1,014 | 39 of 1,012 | 2,026 | NCT01950819 | Trial comparisons |
| Everolimus Plus@Reduced CNI vs MPA Plus Standard@CNI: serious adverse events | 593 of 1,014 | 613 of 1,012 | 2,026 | NCT01950819 | Trial comparisons |
| Everolimus vs Placebo: deaths from any cause | 112 of 896 | 119 of 896 | 1,792 | NCT01674140 | Trial comparisons |
| Everolimus vs Placebo: serious adverse events | 180 of 874 | 77 of 881 | 1,755 | NCT01674140 | Trial comparisons |
| PROMUS vs PROMUS Element: serious adverse events | 237 of 762 | 238 of 768 | 1,530 | NCT00823212 | Trial comparisons |
| Everolimus vs Placebo: deaths from any cause | 139 of 755 | 151 of 744 | 1,499 | NCT01120249 | Trial comparisons |
| Everolimus vs Placebo: serious adverse events | 154 of 740 | 68 of 723 | 1,463 | NCT01120249 | Trial comparisons |
| NIVOLUMAB vs EVEROLIMUS: deaths from any cause | 324 of 406 | 342 of 397 | 803 | NCT01668784 | Trial comparisons |
| NIVOLUMAB vs EVEROLIMUS: serious adverse events | 248 of 406 | 243 of 397 | 803 | NCT01668784 | Trial comparisons |
| Everolimus + Exemestane vs Placebo + Exemestane: Overall Survival (OS) by Number of Deaths | 267 of 485 | 143 of 239 | 724 | NCT00863655 | Trial comparisons |
| Everolimus + Exemestane vs Placebo + Exemestane: serious adverse events | 158 of 482 | 37 of 238 | 720 | NCT00863655 | Trial comparisons |
| Everolimus+ Paclitaxel+ Trastuzumab vs Placebo+ Paclitaxel+ Trastuzumab: deaths from any cause | 23 of 472 | 2 of 238 | 710 | NCT00876395 | Trial comparisons |
| Everolimus+ Paclitaxel+ Trastuzumab vs Placebo+ Paclitaxel+ Trastuzumab: serious adverse events | 173 of 472 | 40 of 238 | 710 | NCT00876395 | Trial comparisons |
| Cabozantinib (XL184) vs Everolimus (Afinitor): serious adverse events | 131 of 331 | 139 of 322 | 653 | NCT01865747 | Trial comparisons |
| Everolimus 10mg / Daily vs Placebo: serious adverse events | 210 of 437 | 89 of 215 | 652 | NCT00879333 | Trial comparisons |
| Everolimus and Low Dose Tacrolimus vs Mycophenolate Mofetil and Standard Dose Tacrolimus: serious adverse events | 154 of 306 | 142 of 304 | 610 | NCT01025817 | Trial comparisons |
| Everolimus + Trastuzumab + Vinorelbine vs Placebo + Trastuzumab + Vinorelbine: serious adverse events | 122 of 280 | 58 of 282 | 562 | NCT01007942 | Trial comparisons |
pipelines-2026-09-18-0.3.1
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL1908360/comparisons